##### 



Exhibit 99.1
 
 IsoTis Extends Private Label with AlloSource for First Generation DBM Products
 IRVINE, CA, USA
      About IsoTis, Inc.
 For information contact:    robert.morocco@isotis.com
 hans.herklots@isotis.com




---



##### 



Certain statements in this press release are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to
managements plans and expectations for future operations, prospects and financial condition. Words
such as strategy, expects, plans, anticipates, believes, will, continues,
estimates, intends, projects, goals, targets and other words of similar meaning are
intended to identify such forward-looking statements. One can also identify them by the fact that
they do not relate strictly to historical or current facts. Such statements are based on the
current expectations of the management of IsoTis only. Undue reliance should not be placed on these
statements because, by their nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of IsoTis. Actual results could differ materially
from current expectations due to a number of factors and uncertainties affecting IsoTis business,
including, but not limited to, the Companys need to raise additional capital to continue
operations, a competitive sales and marketing environment, the effects of the Allosource license
agreement on the Companys ongoing operations, the timely commencement and success of IsoTis
clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or
other regulatory approvals (i.e.,. EMEA, CE), including the risk that the FDA determines that our
Accell Putty and Accell TBM products are not human tissue or class II medical devices, that the
Company is unable to obtain 510(k) clearance for its Accell products, that the FDA requires the
Company to obtain premarket approval of its Accell products prior to continuing their marketing,
that the FDA requires the Company to produce additional clinical data to support approval or
clearance of its products, that the FDA imposes compliance measures against the Company for the
marketing of its Accell products, including imposing fines and injunctions or causing the Company
to recall its Accell products, market acceptance of IsoTis products, effectiveness of IsoTis
distribution channels, development of competing therapies and/or technologies, the terms of any
future strategic alliances, the need for additional capital, the inability to obtain, or meet,
conditions imposed for required governmental and regulatory approvals and consents. IsoTis
expressly disclaims any intent or obligation to update these forward-looking statements except as
required by law. For a more detailed description of the risk factors and uncertainties affecting
IsoTis, refer to the Annual Report on Form 20-F for the fiscal year ended December 31, 2006 of
IsoTis S.A. (the predecessor to IsoTis, Inc.), and its other reports filed with the SEC, IsoTis
S.A.s reports filed from time to time with the Swiss Stock Exchange (SWX), Euronext Amsterdam
N.V., SEDAR at www.sedar.com and the Toronto Stock Exchange (TSX) and the quarterly report on Form
10-Q for the quarter ended March 31, 2007 and other reports filed with the SEC from time to time by
IsoTis, Inc.